Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
S‐adenosyl methionine as monotherapy may leads to lower acceptability. Participants experiencing troublesome adverse effects… compared with tricyclic antidepressant agent (low certainty).
1 finding from 1 review
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether ECT plus standard care changes satisfaction and acceptability of treatment (medium term) ‐ leaving… compared with standard care (very low certainty).
1 finding from 1 review
Acceptability (of intervention): Leaving the studies early – any reason Loss to · patients with treatment compliance for people with serious mental illness
1 finding from 1 review
Treatment non‐acceptability (higher = greater non‐acceptability): end‐of‐intervention · older people with depression
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
Summary of findings table ‐ Cognitive behavioural therapy plus… showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with control (moderate certainty).
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · patients with schizophrenia
Summary of findings table ‐ Antipsychotic dose reduction probably leads to higher leaving the study early ‐ for any reason ‐ overall acceptability… compared with dose continuation (moderate certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
acceptability and safety of treadmill training ‐ No intervention control group (co‐interventions were not similar in both groups) Number of adverse events and drop‐outs · people with stroke
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
S‐adenosyl methionine as monotherapy showed no clear difference in acceptability Participants dropping out of treatment during the… compared with SSRI antidepressant agent (low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
It is very uncertain whether S‐adenosyl methionine as adjunctive treatment changes acceptability Participants dropping out of treatment during the… compared with placebo (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
S‐adenosyl methionine as monotherapy showed no clear difference in acceptability Participants dropping out of treatment during the… compared with placebo (low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
It is very uncertain whether S‐adenosyl methionine as monotherapy changes acceptability Participants dropping out of treatment during the… compared with tricyclic antidepressant agent (very low certainty).
1 finding from 1 review